Glenfield Hospital
Glenfield Hospital
Leicester, United Kingdom12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| Study of Hospitalised Patients With Acute Respiratory Conditions | Chronic Disease, Disease Attributes, Embolism, Embolism and Thrombosis, Hypersensitivity, Immediate, Infections, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiratory Hypersensitivity, asthma, bronchial disorder, bronchiectasis, cardiovascular disorder, chronic obstructive pulmonary disease, immune system disorder, interstitial lung disease, lung disorder, obstructive lung disease, pleural disorder, pneumonia, pulmonary embolism, respiratory system disorder, respiratory tract infectious disorder, vascular disorder | Recruiting | Not stated | 2026-10-06 | NCT05095090 | |
| A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07210723 | |
| A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy | Symptomatic Genetic Dilated Cardiomyopathy (DCM) | Recruiting | Phase 3 | 2026-10-02 | NCT07771465 | |
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression | interstitial lung disease, lung disorder, respiratory system disorder | Recruiting | Phase 3 | 2026-10-01 | NCT07540988 | |
| An Observational Post-marketing Study Using Commercially Approved Biosense Webster (BWI) Medical Devices for the Treatment of Participants With Cardiac Arrhythmias | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder | Recruiting | Not stated | 2026-09-25 | NCT04750798 | |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, cardiovascular disorder, heart disorder, heart failure, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 3 | 2026-09-16 | NCT07037459 | |
| ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | Acute Myocardial Infarction (AMI); Cardiovascular Risk | Active, not recruiting | Phase 3 | 2026-09-09 | NCT06118281 | |
| First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF) | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Not applicable | 2026-09-03 | NCT04203576 | |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 3 | 2026-08-14 | NCT05878769 | |
| Defining the Genetics, Biomarkers and Outcomes for Dilated Cardiomyopathy | Cardiomegaly, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, cardiomyopathy, cardiovascular disorder, dilated cardiomyopathy, heart disorder, hereditary disease, laminopathy | Active, not recruiting | Not stated | 2026-03-27 | NCT03843255 | |
| Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy | Diabetes Complications, Diabetic Cardiomyopathies, Nutritional and Metabolic Diseases, cardiomyopathy, cardiovascular disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Phase 3 | 2022-12-08 | NCT04083339 |